Sagimet Biosciences schedules virtual KOL event on denifanstat acne program

By Public Technologies
  • Sagimet Biosciences schedules a virtual KOL event on denifanstat for September 30, 2026 at 1:00 PM ET; registration: link.
  • Event focus: 52-week Phase 3 open-label extension data from China, update on the planned U.S. AURORA Phase 3 acne trial.
  • U.S. AURORA Phase 3 trial initiation targeted for Q4 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sagimet Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609280700PRIMZONEFULLFEED9834735) on September 28, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk